Cargando…

Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants

BACKGROUND: Disclosure of pathogenic variants to thoracic aortic dissection biobank participants was implemented. The impact and costs, including confirmatory genetic testing in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, were evaluated. METHODS: We exome sequenced 240...

Descripción completa

Detalles Bibliográficos
Autores principales: Beil, Adelyn, Hornsby, Whitney, Uhlmann, Wendy R., Aatre, Rajani, Arscott, Patricia, Wolford, Brooke, Eagle, Kim A., Yang, Bo, McNamara, Jennifer, Willer, Cristen, Roberts, J. Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923508/
https://www.ncbi.nlm.nih.gov/pubmed/33648514
http://dx.doi.org/10.1186/s12920-021-00902-5
_version_ 1783658917322031104
author Beil, Adelyn
Hornsby, Whitney
Uhlmann, Wendy R.
Aatre, Rajani
Arscott, Patricia
Wolford, Brooke
Eagle, Kim A.
Yang, Bo
McNamara, Jennifer
Willer, Cristen
Roberts, J. Scott
author_facet Beil, Adelyn
Hornsby, Whitney
Uhlmann, Wendy R.
Aatre, Rajani
Arscott, Patricia
Wolford, Brooke
Eagle, Kim A.
Yang, Bo
McNamara, Jennifer
Willer, Cristen
Roberts, J. Scott
author_sort Beil, Adelyn
collection PubMed
description BACKGROUND: Disclosure of pathogenic variants to thoracic aortic dissection biobank participants was implemented. The impact and costs, including confirmatory genetic testing in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, were evaluated. METHODS: We exome sequenced 240 cases with thoracic aortic dissection and 258 controls, then examined 11 aortopathy genes. Pathogenic variants in 6 aortopathy genes (COL3A1, FBN1, LOX, PRKG1, SMAD3, and TGFBR2) were identified in 26 participants, representing 10.8% of the cohort (26/240). A second research sample was used to validate the initial findings. Mailed letters to participants disclosed that a potentially disease causing DNA alteration had been identified (neither the gene nor variant was disclosed). Participants were offered clinical genetic counseling and confirmatory genetic testing in a CLIA laboratory. RESULTS: Excluding 6 participants who were deceased or lost to follow-up, 20 participants received the disclosure letter, 10 of whom proceeded with genetic counseling, confirmatory genetic testing, and enrolled in a survey study. Participants reported satisfaction with the letter (4.2 ± 0.7) and genetic counseling (4.4 ± 0.4; [out of 5, respectively]). The psychosocial impact was characterized by low decisional regret (11.5 ± 11.6) and distress (16.0 ± 4.2, [out of 100, respectively]). The average cost for 26 participants was $400, including validation and sending letters. The average cost for those who received genetic counseling and CLIA laboratory confirmation was $605. CONCLUSIONS: Participants were satisfied with the return of clinically significant biobank genetic results and CLIA laboratory testing; however, the process required significant time and resources. These findings illustrate the trade-offs involved for researchers considering returning research genetic results. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12920-021-00902-5.
format Online
Article
Text
id pubmed-7923508
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79235082021-03-02 Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants Beil, Adelyn Hornsby, Whitney Uhlmann, Wendy R. Aatre, Rajani Arscott, Patricia Wolford, Brooke Eagle, Kim A. Yang, Bo McNamara, Jennifer Willer, Cristen Roberts, J. Scott BMC Med Genomics Research Article BACKGROUND: Disclosure of pathogenic variants to thoracic aortic dissection biobank participants was implemented. The impact and costs, including confirmatory genetic testing in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, were evaluated. METHODS: We exome sequenced 240 cases with thoracic aortic dissection and 258 controls, then examined 11 aortopathy genes. Pathogenic variants in 6 aortopathy genes (COL3A1, FBN1, LOX, PRKG1, SMAD3, and TGFBR2) were identified in 26 participants, representing 10.8% of the cohort (26/240). A second research sample was used to validate the initial findings. Mailed letters to participants disclosed that a potentially disease causing DNA alteration had been identified (neither the gene nor variant was disclosed). Participants were offered clinical genetic counseling and confirmatory genetic testing in a CLIA laboratory. RESULTS: Excluding 6 participants who were deceased or lost to follow-up, 20 participants received the disclosure letter, 10 of whom proceeded with genetic counseling, confirmatory genetic testing, and enrolled in a survey study. Participants reported satisfaction with the letter (4.2 ± 0.7) and genetic counseling (4.4 ± 0.4; [out of 5, respectively]). The psychosocial impact was characterized by low decisional regret (11.5 ± 11.6) and distress (16.0 ± 4.2, [out of 100, respectively]). The average cost for 26 participants was $400, including validation and sending letters. The average cost for those who received genetic counseling and CLIA laboratory confirmation was $605. CONCLUSIONS: Participants were satisfied with the return of clinically significant biobank genetic results and CLIA laboratory testing; however, the process required significant time and resources. These findings illustrate the trade-offs involved for researchers considering returning research genetic results. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12920-021-00902-5. BioMed Central 2021-03-01 /pmc/articles/PMC7923508/ /pubmed/33648514 http://dx.doi.org/10.1186/s12920-021-00902-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Beil, Adelyn
Hornsby, Whitney
Uhlmann, Wendy R.
Aatre, Rajani
Arscott, Patricia
Wolford, Brooke
Eagle, Kim A.
Yang, Bo
McNamara, Jennifer
Willer, Cristen
Roberts, J. Scott
Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants
title Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants
title_full Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants
title_fullStr Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants
title_full_unstemmed Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants
title_short Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants
title_sort disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923508/
https://www.ncbi.nlm.nih.gov/pubmed/33648514
http://dx.doi.org/10.1186/s12920-021-00902-5
work_keys_str_mv AT beiladelyn disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants
AT hornsbywhitney disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants
AT uhlmannwendyr disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants
AT aatrerajani disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants
AT arscottpatricia disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants
AT wolfordbrooke disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants
AT eaglekima disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants
AT yangbo disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants
AT mcnamarajennifer disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants
AT willercristen disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants
AT robertsjscott disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants